retatrutide what is retatrutide clinical trials UK: 2026 Trial & Approval Guide – Trim Today, we shared new data

Morgan & Morgan represents Bjorklund

Tirzepatide and semaglutide are generally safe, but they may not be suitable for everyone, including: People with a personal or family history of thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN2) People with a personal or family history of pancreatitis People with known hypersensitivity to any component of the medication People who are pregnant, breastfeeding, and planning to become pregnant Always consult a healthcare provider before starting a new medication

Studies show that 8-9% of patients experience diarrhea, while nausea remains the most common complaint

Eden Health has paused its compounded GLP-1 program (both semaglutide and tirzepatide) for new patient enrollment as of mid-2026

Without targeted studies, healthcare providers may be cautious in prescribing semaglutide off-label for RA